To further analyse the effects of NF-κB/miR-590/EHD1 on the tumourigenicity and erlotinib sensitivity of NSCLC cells, PC9/GR cells treated with PDTC were injected into BALB/c nude mice; the mice began receiving erlotinib treatment when tumour volumes reached 100 mm3. The gene discussed is EHD1; the disease is neoplasm.